Table 5. Percentage of antimicrobial resistance of invasive Streptococcus pneumoniae serotypes collected, 2022.
| Serotype | Percentage of isolates with antimicrobial resistancea | |||||||
|---|---|---|---|---|---|---|---|---|
| PEN | AXO | ERY | CLA | CLI | CHL | DOX | SXT | |
| 1b | - | - | - | - | - | - | 33% | 33% |
| 3b | - | - | 4% | 4% | 1% | 6% | 6% | 1% |
| 4b | - | - | 9% | 9% | 7% | 3% | 14% | 12% |
| 14b | 75% | - | 50% | 50% | 50% | - | 50% | 75% |
| 7Fb | - | - | 3% | 3% | - | - | - | - |
| 9Vb | 69% | 3% | 72% | 71% | - | - | 70% | 72% |
| 18Cb | - | - | 33% | 33% | 17% | - | 33% | 17% |
| 19Ab | 40% | 2% | 77% | 77% | 58% | 2% | 47% | 42% |
| 19Fb | 4% | - | 4% | 4% | 4% | - | 4% | 4% |
| 23Fb | 67% | - | 67% | 67% | 33% | 33% | 33% | 67% |
| 22Fc | - | - | 50% | 49% | 2% | 2% | 3% | - |
| 33Fc | - | - | 73% | 73% | - | - | - | 27% |
| 15B/Cd,e | 3% | - | 25% | 27% | 10% | - | 18% | 3% |
| 10Ad | - | - | 29% | - | - | - | - | - |
| 11Ad | 3% | - | 33% | 34% | 3% | - | 3% | 3% |
| 12Fd | - | - | 30% | 31% | - | 3% | 35% | 36% |
| 8d | - | - | 3% | 3% | - | - | 2% | - |
| 9Nf | 5% | - | 5% | 5% | - | - | 8% | 3% |
| 17Ff | 22% | - | 11% | 11% | - | - | - | - |
| 20f | - | - | 8% | 9% | 8% | - | 11% | 2% |
| 6C | - | - | 50% | 50% | 17% | 17% | 33% | 17% |
| 6D | - | - | - | - | - | 100% | 100% | 100% |
| 7C | - | - | - | - | - | - | 8% | 69% |
| 13 | - | - | 40% | 40% | 40% | - | 60% | 60% |
| 15A | 15% | - | 38% | 38% | 31% | 4% | 27% | 4% |
| 16F | - | - | 5% | 5% | 5% | 5% | 5% | - |
| 17A | - | - | 100% | 100% | 100% | - | 100% | - |
| 23A | - | - | 26% | 29% | 26% | - | 29% | 9% |
| 23B | - | - | 11% | 8% | - | - | - | 29% |
| 24A | - | - | - | - | - | - | - | 100% |
| 24F | - | - | 67% | 67% | 67% | - | 67% | - |
| 28A | - | - | - | - | - | 50% | 50% | - |
| 35B | 57% | - | 36% | 36% | 7% | 7% | 7% | 14% |
| 31 | - | - | 17% | 17% | - | - | - | - |
| 34 | 8% | - | - | - | - | - | - | - |
| 38 | - | - | 40% | 40% | - | - | 40% | 20% |
Abbreviations: AXO, ceftriaxone using the parenteral meningitis interpretive standard; CHL, chloramphenicol; CLA, clarithromycin; CLI, clindamycin; DOX, doxycycline; ERY, erythromycin; PEN, penicillin using the parenteral meningitis Clinical and Laboratory Standards Institute interpretive standard; SXT, trimethoprim/sulfamethoxazole
a “-” denotes no resistance (0%) to the antimicrobial
b Component of PCV13
c Component of PCV15
d Component of PCV20
e Serotypes 15B and 15C were grouped together as 15B/C because of reported reversible switching between them in vivo during infection, making it difficult to precisely differentiate between the two types (18,19)
f Component of PPV23